MedTrace Logo

Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer

NCT05230771 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-04-01

No results posted yet for this study

Summary

This single-center, prospective study was conducted to investigate the efficacy and safety of palliative surgery after translational therapy in the treatment of metastatic gastric cancer. The primary endpoint was 2-year overall survival (OS) rate. Secondary endpoints were median OS, progression-free survival (PFS), 1-year OS, adverse events (AE), severe AE, the quality of life (QOL) and treatment cost.

Conditions

  • Metastatic Gastric Cancer
  • Surgery
  • Chemotherapy

Interventions

COMBINATION_PRODUCT

Palliative surgery after translational therapy

A total, distal, or proximal gastrectomy with D1 lymph node dissection was done depending on tumour after translational therapy . location.

DRUG

Chemotheraoy along

Patients receive only the prescribed chemotherapy.

Sponsors & Collaborators

  • Fujian Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2024-03-01
Completion
2027-03-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05230771 on ClinicalTrials.gov